重组人甲状旁腺素（1-34）与降钙素治疗绝经后骨质疏松临床观察

周芸帆; 杨刚毅; 李伶; 刘东方; 郭常辉; 李生兵; 陈文雯

doi:10.13406/j.cnki.cyxb.2010.02.017

您当前的位置：

首页 >

文章列表页 >

重组人甲状旁腺素（1-34）与降钙素治疗绝经后骨质疏松临床观察

临床研究 | 更新时间：2024-01-17

- 重组人甲状旁腺素（1-34）与降钙素治疗绝经后骨质疏松临床观察
- A comparison of rhPTH(1-34) and calcitonin therapy for post-menopausal women with osteoporosis
- 重庆医科大学学报 2010年35卷第2期页码：238-240
- 作者机构：
  
  1. 重庆医科大学附属第二医院内分泌科
  2. 重庆医科大学检验系临床生化教研室
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.2010.02.017
  中图分类号： R580
- 纸质出版日期：2010，
扫描看全文
[1]周芸帆,杨刚毅,李伶,刘东方,郭常辉,李生兵,陈文雯.重组人甲状旁腺素(1-34)与降钙素治疗绝经后骨质疏松临床观察[J].重庆医科大学学报,2010,35(02):238-240.

ZHOU Yun-fan, et al. A comparison of rhPTH(1-34) and calcitonin therapy for post-menopausal women with osteoporosis[J]. Journal of Chongqing Medical University, 2010,35(2):238-240.
[1]周芸帆,杨刚毅,李伶,刘东方,郭常辉,李生兵,陈文雯.重组人甲状旁腺素(1-34)与降钙素治疗绝经后骨质疏松临床观察[J].重庆医科大学学报,2010,35(02):238-240. DOI： 10.13406/j.cnki.cyxb.2010.02.017.

ZHOU Yun-fan, et al. A comparison of rhPTH(1-34) and calcitonin therapy for post-menopausal women with osteoporosis[J]. Journal of Chongqing Medical University, 2010,35(2):238-240. DOI： 10.13406/j.cnki.cyxb.2010.02.017.

摘要

目的:观察对比重组人甲状旁腺素（1-34）[Recombinant human parat-hyroid hormone

rhPTH（1-34）]

后简称PTH]

和降钙素（Calcitionin

CT）对绝经后妇女骨质疏松症的疗效。方法:符合入选标准的56例绝经后妇女骨质疏松患者随机分为两组:PTH组（n=30）皮下注射重组人甲状旁腺素20μg每天1次;CT组（n=26）肌肉注射降钙素20IU每周1次

两组均每日给予钙尔奇D 600 mg/d

连续治疗6个月。比较治疗前后腰椎(L

2-4

)骨密度及T值

血钙磷及碱性磷酸酶（Alkaline phosphatase

AKP）等指标的变化及观察有无不良反应。结果:治疗后PTH组和CT组腰椎(L

2-4

)骨密度（Bone mineral density

BMD）均有明显增加[PTH组:（-4.09±1.30 vs-3.70±1.17）SD;CT组:（-4.03±1.27 vs-3.74±1.19）SD

均P

0.01]。但两组间比较无明显差异。PTH组治疗后AKP明显增高[（88.2±28.2 vs 123.2±34.2）U/L

0.05]

而CT组无明显变化。另外

CT组治疗后血清胆固醇（Total cholesterol

TC）降低[（5.64±0.61 vs 5.22±0.70）mmol/L

0.01]。两组均无严重不良反应发生。结论:rhPTH（1-34）与降钙素都能显著提高BMD和缓解骨质疏松症状

对于治疗骨质疏松安全有效。

Abstract

Objective:To observe the therapeutic effects of recombinant human parathyroid hormone[rhPTH（1-34）]and calcitonin on post-menopausal women with osteoporosis.Methods:56 postmenopausal women with osteoporosis were randomly divided in to PTH （n=30）and CT（n=26）groups.The patients in PTH group were treated with rhPTH（1-34）20μg/d by subcutaneous injection

and those in CT group were treated with calcitonin 20 IU/week by intramuscular injection.All patients were given oral calcium（Ca 600 mg+Vit D3 125 U

QD）.All the treatments lasted for six months.Lumbar spine(L

2～4

)bone mineral density（BMD）

T value

serum calcium

serum phosphate and serum alkline phosphatase were measured in two groups before and after treatment.Results:In two groups BMD was remarkably increased after treatment[PTH:（0.74±0.09 vs 0.76±0.08）g/cm

;CT:（0.74±0.09 vs 0.76±0.09）g/cm

0.01]. T-Scores were also significantly increased after treatment[PTH:（-4.09±1.30 vs-3.70±1.17）SD

CT:（-4.03±1.27 vs-3.74±1.19） SD

0.01].But there were no significant differences between two groups.After treatment

AKP levels were obviously increased in PTH group[（88.2±28.2 vs 123.2±34.2）U/L

0.05]

whereas serum cholesterol significantly decreased in CT group[（5.64±0.61 vs 5.22±0.70）mmol/L

0.01].Conclusion:Both rhPTH（1-34）and calcitonin treatment can increase lumbar spine BMD and relievesymptoms in patients with osteoporosis.

关键词

重组人甲状旁腺素降钙素骨质疏松症骨密度

Keywords

rhPTH(1-34)Calcitoninosteoporosisbone mineral density

references

浏览量

183

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

持续静压力环境下MC3T3-E1细胞的基因测序分析

PKP术后新发椎体骨折危险因素分析

绝经期女性骨密度调查及相关因素分析

维生素D和钙缺乏对中鸡骨骼发育的影响